Vanderbilt Vaccine Center

VUMC joins effort to stop spread of two deadly viruses

Researchers at Vanderbilt University Medical Center are participating in a national effort to develop vaccines and other treatments as countermeasures to prevent the spread of two emerging and deadly viruses — Nipah and Hendra.

VUMC chikungunya antibody set to enter clinical trial

A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.

James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.

Researchers push forward frontiers of vaccine science

Using sophisticated gene sequencing and computing techniques, researchers at Vanderbilt University Medical Center and the San Diego Supercomputer Center have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.

Designing antibodies to fight the flu

Vanderbilt investigators said their work shows that computational design can improve the ability of naturally occurring antibodies to recognize different flu strains and may hasten the development of more effective flu therapies and vaccines.

Research assistant Mahsa Majedi loads reagent used in DNA sample preparation in the genomics lab. She is part of a team of more than a dozen people at VUMC who are “sprinting” to develop — within 90 days — an antibody-based treatment to stop the spread of the Zika virus.

VUMC scientists ‘sprint’ to find anti-Zika antibodies

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

Dae Kwang Jung, left, Brian Engelhardt, MD, MSCI, and colleagues are studying why stem cell transplant patients are at risk of developing diabetes.

Research explores link between stem cell transplant, diabetes

About a decade ago, at the beginning of his career in academic medicine, Brian Engelhardt, MD, MSCI, noticed that many of his patients receiving a stem cell transplant for their blood cancer ended up with diabetes.

1 5 6 7 8 9 14